SITAGEN M 50MG 1000MG TAB (10S)
SITAGEN M 50mg/1000mg Tablets contain Sitagliptin 50mg and Metformin Hydrochloride 1000mg and are manufactured by Ferozsons Laboratories Ltd. This dual-action antidiabetic medicine is prescribed for adults with Type 2 Diabetes Mellitus to help achieve better blood glucose control when diet, exercise, or single-drug therapy is insufficient. Sitagliptin enhances the body's natural insulin response after meals, while Metformin reduces glucose production by the liver and improves insulin sensitivity. Together, they provide effective blood sugar management and help reduce the risk of long-term diabetic complications.
Uses
- Treatment of Type 2 Diabetes Mellitus
- Improves blood glucose control
- Used alongside a healthy diet and regular exercise
- May be prescribed with other antidiabetic medications when appropriate
- Helps reduce the risk of diabetes-related complications through improved glycemic control
Advantages / Benefits
- Contains Sitagliptin 50mg + Metformin Hydrochloride 1000mg
- Dual mechanism for effective blood sugar control
- Improves insulin sensitivity
- Reduces glucose production by the liver
- Helps lower HbA1c levels
- Convenient fixed-dose combination tablet, reducing pill burden
Possible Side Effects
Common side effects may include:
- Nausea
- Diarrhea
- Stomach upset
- Headache
- Loss of appetite
- Metallic taste
- Mild upper respiratory symptoms
Serious but uncommon side effects include pancreatitis, lactic acidosis (associated with Metformin), severe allergic reactions, or kidney problems. Seek immediate medical attention if severe abdominal pain, difficulty breathing, or unusual weakness develops.
Pharmacist's Advice
- Take with meals to reduce stomach upset.
- Follow your prescribed diabetic diet and exercise plan.
- Monitor your blood glucose regularly.
- Avoid excessive alcohol consumption while taking this medicine.
- Inform your doctor if you have kidney disease, liver disease, or a history of pancreatitis.
- Do not discontinue treatment without consulting your healthcare provider.
- Regular monitoring of kidney function and HbA1c is recommended during long-term therapy.